UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 204

Sortiert nach

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Blood, 2015-02, Vol.125 (9), p.1394-1402

2015

Volltextzugriff (PDF)

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

The New England journal of medicine, 2015-09, Vol.373 (10), p.920-928

2015

Volltextzugriff (PDF)

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

Clinical cancer research, 2015-09, Vol.21 (18), p.4055-4061

2015

Volltextzugriff (PDF)

High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry

Journal of clinical oncology, 2002-02, Vol.20 (3), p.743-750

Berry, D. A.

2002

Volltextzugriff (PDF)

Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer

Journal of clinical oncology, 2015-02, Vol.33 (5), p.522-523

2015

Volltextzugriff (PDF)

Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians

The American journal of the medical sciences, 2021-08, Vol.362 (2), p.113-121

2021

Volltextzugriff (PDF)

Clinical Utility of a Blood-based Protein Assay on Diagnostic Colonoscopy Referrals for Elevated-risk Colorectal Cancer Patients in Primary Care

American journal of clinical oncology, 2019-09, Vol.42 (9), p.687

2019

Volltextzugriff (PDF)

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Blood, 2013-07, Vol.122 (4), p.499-506

2013

Volltextzugriff (PDF)

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Blood, 2015-12, Vol.126 (23), p.57-57

2015

Volltextzugriff (PDF)

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Blood, 2016-12, Vol.128 (22), p.1938-1938

2016

Volltextzugriff (PDF)

A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

British journal of haematology, 2014-11, Vol.167 (4), p.466-477

2014

Volltextzugriff (PDF)

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

Blood, 2013-11, Vol.122 (21), p.2745-2745

2013

Volltextzugriff (PDF)

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

Blood, 2013-11, Vol.122 (21), p.3181-3181

2013

Volltextzugriff (PDF)

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Blood, 2012-11, Vol.120 (21), p.4058-4058

2012

Volltextzugriff (PDF)

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

Blood, 2012-11, Vol.120 (21), p.179-179

2012

Volltextzugriff (PDF)

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

Blood, 2011-11, Vol.118 (21), p.957-957

2011

Volltextzugriff (PDF)

Plasma cell disorders: myeloma and related conditions. Diagnosis and management

Journal of the South Carolina Medical Association, 2003-04, Vol.99 (4), p.88

Spitzer, Gary

2003

Volltextzugriff (PDF)

Transplantation of CD34+ Peripheral Blood Progenitor Cells After High-Dose Chemotherapy for Patients With Advanced Multiple Myeloma

Blood, 1995-07, Vol.86 (1), p.390-397

1995

Volltextzugriff (PDF)

Pegfilgrastim Appears Equivalent to Daily Dosing of Filgrastim to Treat Neutropenia After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin Lymphoma

Clinical lymphoma, myeloma and leukemia, 2010-06, Vol.10 (3), p.186-191

2010

Volltextzugriff (PDF)

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Blood, 2008-11, Vol.112 (11), p.2780-2780

2008

Volltextzugriff (PDF)

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin's Lymphoma (NHL)

Blood, 2007-11, Vol.110 (11), p.4936-4936

2007

Volltextzugriff (PDF)

Engraftment After Infusion of CD34+ Marrow Cells in Patients With Breast Cancer or Neuroblastoma

Blood, 1991-04, Vol.77 (8), p.1717-1722

1991

Volltextzugriff (PDF)

Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit

Journal of clinical oncology, 1994-04, Vol.12 (4), p.661-670

1994

Volltextzugriff (PDF)

Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts

Transfusion (Philadelphia, Pa.), 1997-07, Vol.37 (7), p.737-748

1997

Volltextzugriff (PDF)

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(175)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(204)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(138)
Science & Technology
(131)
Life Sciences & Biomedicine
(120)
Female
(78)
Biological And Medical Sciences
(65)
Male
(63)
Medical Sciences
(63)
Adult
(59)
Middle Aged
(54)
Oncology
(48)
Bone Marrow Transplantation
(37)
Combined Modality Therapy
(33)
Hematology
(31)
Aged
(28)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(25)
Pharmacology. Drug Treatments
(23)
Adolescent
(22)
Cyclophosphamide - Administration & Dosage
(20)
Transplantation, Autologous
(20)
Antineoplastic Agents
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry

Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer

Biochemical Diagnosis of Acute Hepatic Porphyria: Updated Expert Recommendations for Primary Care Physicians

Clinical Utility of a Blood-based Protein Assay on Diagnostic Colonoscopy Referrals for Elevated-risk Colorectal Cancer Patients in Primary Care

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses

A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

Plasma cell disorders: myeloma and related conditions. Diagnosis and management

Transplantation of CD34+ Peripheral Blood Progenitor Cells After High-Dose Chemotherapy for Patients With Advanced Multiple Myeloma

Pegfilgrastim Appears Equivalent to Daily Dosing of Filgrastim to Treat Neutropenia After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin Lymphoma

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin's Lymphoma (NHL)

Engraftment After Infusion of CD34+ Marrow Cells in Patients With Breast Cancer or Neuroblastoma

Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit

Transfusions of granulocyte-colony-stimulating factor-mobilized granulocyte components to allogeneic transplant recipients: analysis of kinetics and factors determining posttransfusion neutrophil and platelet counts

Suchergebnisse filtern